Novanta heads into its third-quarter report with an awkward mismatch between business momentum and share price. Three months ago, management described a company firing on all cylinders: organic growth jumped to 9%, every business unit grew, guidance rose across the board, and the largest acquisition in company history, Riverpoint Medical, closed. The stock has since fallen 14%, trailing the S&P 500 by about 12 percentage points. That gap makes the November 9 report, due after the close, less a test of whether Novanta can grow and more a test of whether that growth is clean enough to convince a skeptical market.

Wall Street expects earnings of $0.97 per share on revenue of $300.5 million. That sits squarely inside management's guidance of $0.95 to $1.00 per share and $300 million to $304 million in sales, with revenue consensus tucked slightly below the midpoint. The headline growth looks dramatic, with sales up more than 21% from $247.8 million a year ago, but much of that comes from Riverpoint, which management expects to contribute roughly $65 million in revenue and $25 million in EBITDA over the second half. Earnings growth of about 11.5% lags well behind revenue, a reminder that the deal was financed with debt. Interest expense is stepping up to roughly $9 million a quarter, and leverage has swung from a net cash position to about 2.7 times on a gross pro forma basis. Because the Street is simply matching guidance rather than reaching beyond it, the bar is reasonable, but Novanta has already raised its full-year targets, so another increase would require evidence that the core business, not just the acquisition, is pulling ahead.

Margins are the most important swing factor. Adjusted gross margin climbed to 47% last quarter, and management guided to about 48% for the second half, a step that would confirm earlier promises that tariff lag and factory transfer costs were temporary. The weak spot was the medical solutions segment, where gross margin slid to roughly 41% on precision medicine mix and site rationalization expenses. Management called for a material sequential rebound this quarter. If that recovery shows up alongside Riverpoint's higher-margin consumables, the margin story strengthens considerably. If medical margins stay stuck near 41%, investors may conclude that restructuring costs, including the two newly announced factory closures, are dragging on longer than advertised.

Organic growth needs to hold up as well. Management guided advanced industrial technologies to 12% to 14% growth, powered by new products and generative AI exposure that reached about 17% of revenue. Early signs of follow-through on the first meaningful humanoid servo-drive orders and the doubling of China air-bearing spindle capacity would help show these catalysts are moving from promise to revenue. On the other side, precision medicine is expected to decline this quarter, and the timeline for a life science recovery has already slipped to late 2027. Any further deferral would chip at credibility. The 0.79 book-to-bill in advanced surgery, which management attributed to custom order timing, should snap back if that explanation holds.

Sentiment has cooled, with bearish readings deepening from 8.6% to 14.4% ahead of the report. The stock, at $145.76, sits just above its 200-day moving average and in the lower half of its post-earnings range between $128.57 and $176.38, suggesting the market has priced in some doubt without capitulating.

Ultimately, the quarter hinges on whether Novanta can show that Riverpoint is integrating smoothly and that medical margins are recovering as promised. Delivering both would validate the accelerating narrative management laid out last quarter. Falling short on either would give the market's skepticism fresh justification.